Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P49221
UPID:
TGM4_HUMAN
Alternative names:
Fibrinoligase; Prostate transglutaminase; Prostate-specific transglutaminase; Transglutaminase P; Transglutaminase-4
Alternative UPACC:
P49221; Q16707; Q96QN4
Background:
Protein-glutamine gamma-glutamyltransferase 4, known by alternative names such as Fibrinoligase, Prostate transglutaminase, and Transglutaminase-4, plays a pivotal role in the mammalian reproductive process. It is instrumental in catalyzing the cross-linking of proteins and the conjugation of polyamines to specific proteins in the seminal tract, highlighting its critical function in fertility and reproductive health.
Therapeutic significance:
Understanding the role of Protein-glutamine gamma-glutamyltransferase 4 could open doors to potential therapeutic strategies. Its involvement in the seminal tract's biochemical processes makes it a target of interest for addressing reproductive health issues and enhancing fertility treatments.